Share on StockTwits

Albany Molecular Research (NASDAQ:AMRI) SVP Steven R. Hagen sold 2,500 shares of the company’s stock on the open market in a transaction dated Tuesday, June 3rd. The stock was sold at an average price of $16.93, for a total transaction of $42,325.00. Following the completion of the transaction, the senior vice president now directly owns 31,730 shares of the company’s stock, valued at approximately $537,189. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link.

Shares of Albany Molecular Research (NASDAQ:AMRI) traded up 1.82% during mid-day trading on Thursday, hitting $17.37. 148,898 shares of the company’s stock traded hands. Albany Molecular Research has a 52-week low of $9.71 and a 52-week high of $20.55. The stock’s 50-day moving average is $15.96 and its 200-day moving average is $13.90. The company has a market cap of $546.4 million and a price-to-earnings ratio of 56.30.

Albany Molecular Research (NASDAQ:AMRI) last posted its quarterly earnings results on Tuesday, May 6th. The company reported $0.16 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.23 by $0.07. The company had revenue of $51.00 million for the quarter, compared to the consensus estimate of $62.19 million. Analysts expect that Albany Molecular Research will post $0.82 EPS for the current fiscal year.

A number of research firms have recently commented on AMRI. Analysts at TheStreet upgraded shares of Albany Molecular Research from a “hold” rating to a “buy” rating in a research note on Wednesday. Finally, analysts at Zacks downgraded shares of Albany Molecular Research from an “outperform” rating to a “neutral” rating in a research note on Tuesday, April 15th. They now have a $17.80 price target on the stock.

Albany Molecular Research, Inc (NASDAQ:AMRI) is a contract research and manufacturing company.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.